Company / Return on Equity (ROE)
Moderna Return on Equity (ROE) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-32.6%
FY2025
5-year range
-43.7% / -29.2%
FY2021-FY2025
Trend
+0.2%
vs FY2024
Sector context
#105 of 190
Health Care
What the data says
Moderna reports negative total equity of -32.6% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-32.6% in FY2025 with a 5-year CAGR of -3.4%.
Improved from -34.0% to -32.6% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -3.4pp
- 5-Year Change
- -3.4pp
- 10-Year Change
- -
Sector benchmark
#105 of 190 in Health CareTop 55% of 190This company -32.6% Sector average -50.3%
▼
+35.2% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 0.2% year-over-year.
- Currently 17.7pp above the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2018.
- Lowest return on equity (roe) in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 1.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -32.6% | +0.2% |
| FY2024 | -32.7% | +4.0% |
| FY2023 | -34.0% | -16.7% |
| FY2022 | -29.2% | +33.3% |
| FY2021 | -43.7% | -49.9% |
| FY2020 | -29.2% | +33.3% |
| FY2019 | -43.7% | -73.9% |
| FY2018 | -25.1% | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026